Pharmacogenomics and Patient Care: One Size Does Not Fit All
暂无分享,去创建一个
Yusuke Nakamura | Richard M Weinshilboum | Naoyuki Kamatani | Mark J. Ratain | Kathleen M. Giacomini | Sook Wah Yee | Yusuke Nakamura | R. Weinshilboum | M. Ratain | K. Giacomini | S. Yee | N. Kamatani
[1] V. Menon,et al. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. , 2012, Archives of internal medicine.
[2] Jocelyn Kaiser,et al. Clinical medicine. Biomarker tests need closer scrutiny, IOM concludes. , 2012, Science.
[3] P. Neven,et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. , 2012, Journal of the National Cancer Institute.
[4] R. Altman,et al. Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.
[5] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.
[6] Joan Scott,et al. Risky Business: Risk Perception and the Use of Medical Services among Customers of DTC Personal Genetic Testing , 2012, Journal of Genetic Counseling.
[7] Russ B. Altman,et al. Using Multiple Microenvironments to Find Similar Ligand-Binding Sites: Application to Kinase Inhibitor Binding , 2011, PLoS Comput. Biol..
[9] Matthias Griese,et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.
[10] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.
[11] C. Sotozono,et al. A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2011, The Pharmacogenomics Journal.
[12] N. Enomoto,et al. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. , 2011, Human molecular genetics.
[13] Liewei Wang. FKBP51 regulation of AKT/protein kinase B phosphorylation. , 2011, Current opinion in pharmacology.
[14] K. Sangkuhl,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy , 2011, Clinical pharmacology and therapeutics.
[15] R. Altman,et al. Detecting Drug Interactions From Adverse‐Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels , 2011, Clinical pharmacology and therapeutics.
[16] M. Daly,et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. , 2011, Gastroenterology.
[17] D. Roden,et al. The Phenotype Standardization Project: Improving Pharmacogenetic Studies of Serious Adverse Drug Reactions , 2011, Clinical pharmacology and therapeutics.
[18] Michael R. Johnson,et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.
[19] R. Altman,et al. Pharmacogenomics: “Noninferiority” Is Sufficient for Initial Implementation , 2011, Clinical pharmacology and therapeutics.
[20] M. Relling,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapeutics.
[21] C. Freeman,et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes , 2010, Nature Genetics.
[22] Yusuke Nakamura,et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] P. Muglia,et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. , 2010, The American journal of psychiatry.
[24] H. Wolinsky,et al. Direct-to-consumer genome testing: opportunities for pharmacogenomics research? , 2010, Pharmacogenomics.
[25] S. Lewitzky,et al. OC-035 Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a diagnostic test accuracy meta-analysis , 2010, Gut.
[26] Paul T. Williams,et al. Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations , 2010, PloS one.
[27] Jacques Fellay,et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C , 2010, Nature.
[28] Vladimir I. Vladimirov,et al. Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects , 2010, Biological Psychiatry.
[29] Jaekyu Shin,et al. Survey on warfarin pharmacogenetic testing among anticoagulation providers. , 2009, Pharmacogenomics.
[30] M. Beckmann,et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.
[31] A. Koike,et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.
[32] J. O’Connell,et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.
[33] M. Daly,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.
[34] F. Collins,et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.
[35] P. Negulescu,et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.
[36] E. Antman,et al. Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.
[37] R. Nussbaum,et al. Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin , 2009, Journal of General Internal Medicine.
[38] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[39] M. Rieder,et al. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.
[40] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[41] M. Rieder,et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. , 2008, Blood.
[42] H. Faruki,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, Personalized medicine.
[43] H. Guchelaar,et al. Pharmacogenetics: From Bench to Byte , 2008, Clinical pharmacology and therapeutics.
[44] S. Mallal,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.
[45] Marc S. Williams,et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin , 2008, Genetics in Medicine.
[46] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[47] N. Risch,et al. The importance of race and ethnic background in biomedical research and clinical practice. , 2003, The New England journal of medicine.
[48] M. Relling,et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.
[49] R. Weinshilboum,et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.
[50] R. Weinshilboum,et al. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism , 1989, Clinical pharmacology and therapeutics.
[51] M. Dolan,et al. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. , 2012, Pharmacogenomics.
[52] P. Buckley. Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects , 2011 .
[53] M Ingelman-Sundberg,et al. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity , 2005, The Pharmacogenomics Journal.
[54] Yuan-Tsong Chen,et al. A marker for Stevens–Johnson syndrome , 2004 .
[55] R. Schilsky,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.